Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol is focusing on rheumatoid arthritis patients who do not respond to TNF inhibitors. The initial launch material will come from Bristol's Syracuse, N.Y. facility; the company will rely on contract manufacturer Lonza to provide additional supply once a supplemental BLA is approved.
You may also be interested in...
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee
Arthritis committee is expected to discuss the increased risk of infections when Orencia (abatacept) is used in combination with other biologic rheumatoid arthritis therapies during the Sept. 6 review of Bristol's drug.